13C MRS and LC-MS flux analysis of tumor intermediary metabolism

Frontiers in Oncology

Volumn 6, Issue JUN, 2016, Pages

  Shestov, Alexander A ^a   Lee, Seung Cheol ^a   Nath, Kavindra ^a   Guo, Lili ^b   Nelson, David S ^a   Roman, Jeffrey C ^a   Leeper, Dennis B ^c   Wasik, Mariusz A ^b   Blair, Ian A ^b   Glickson, Jerry D ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

13C liquid chromatography mass spectrometry; 13C magnetic resonance spectroscopy; Cancer metabolism; Isotopolome; Isotopomer; Metabolic flux analysis; Metabolic modeling; Sensitivity analysis

Indexed keywords

GLUCOSE TRANSPORTER; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CARBON NUCLEAR MAGNETIC RESONANCE; CITRIC ACID CYCLE; GENETIC ANALYSIS; GLUCOSE INTAKE; GLYCOLYSIS; HUMAN; HUMAN CELL; HYPERGLYCEMIA; ISOTOPE LABELING; LACTATE BLOOD LEVEL; LIPOGENESIS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MELANOMA; MELANOMA CELL LINE; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; NUCLEAR OVERHAUSER EFFECT; OXYGEN CONSUMPTION; PENTOSE PHOSPHATE CYCLE;

EID: 84982833604     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2016.00135     Document Type: Article

References (102)

1. Chance EM, Seeholzer SH, Kobayashi K, Williamson JR. Mathematical-analysis of isotope labeling in the citric-acid cycle with applications to C-13 NMR-studies in perfused rat hearts. J Biol Chem (1983) 258:13785-94.
2. Chatham JC, Forder JR, Glickson JD, Chance EM. Calculation of absolute metabolic flux and the elucidation of the pathways of glutamate labeling in perfused rat-heart by C-13 NMR-spectroscopy and nonlinear least-squares analysis. J Biol Chem (1995) 270:7999-8008. doi: 10.1074/jbc.270.14.7999
3. Jeffrey FMH, Reshetov A, Storey CJ, Carvalho RA, Sherry AD, Malloy CR. Use of a single C-13 NMR resonance of glutamate for measuring oxygen consumption in tissue. Am J Physiol Endocrinol Metab (1999) 277:E1111-21.
4. Malloy CR, Sherry AD, Jeffrey FMH. Carbon flux through citric-acid cycle pathways in perfused heart by C-13 NMR-spectroscopy. FEBS Lett (1987) 212:58-62. doi:10.1016/0014-5793(87)81556-9
5. Weiss RG, Kalil-Filho R, Herskowitz A, Chacko VP, Litt M, Stern MD, et al. Tricarboxylic-acid cycle activity in postischemic rat hearts. Circulation (1993) 87:270-82. doi:10.1161/01.CIR.87.1.270
6. Yu X, White LT, Doumen C, Damico LA, LaNoue KF, Alpert NM, et al. Kinetic analysis of dynamic C-13 NMR spectra: metabolic flux, regulation, and compartmentation in hearts. Biophys J (1995) 69:2090-102. doi:10.1016/S0006-3495(95)80080-9
7. Gruetter R, Seaquist ER, Ugrubil K. A mathematical model of compartmentalized neurotransmitter metabolism in the human brain. Am J Physiol Endocrinol Metab (2001) 281:E100-12.
8. Mason GF, Gruetter R, Rothman DL, Behar KL, Shulman RG, Novotny EJ. Simultaneous determination of the rates of the TCA cycle, glucose-utilization, alpha-ketoglutarate glutamate exchange, and glutamine synthesis in human brain by NMR. J Cereb Blood Flow Metab (1995) 15:12-25. doi:10.1038/jcbfm.1995.2
9. Mason GF, Rothman DL, Behar KL, Shulman RG. NMR determination of the TCA cycle rate and alpha-ketoglutarate glutamate exchange-rate in rat-brain. J Cereb Blood Flow Metab (1992) 12:434-47. doi:10.1038/jcbfm.1992.61
10. Befroy DE, Perry RJ, Jain N, Dufour S, Cline GW, Trimmer JK, et al. Direct assessment of hepatic mitochondrial oxidative and anaplerotic fluxes in humans using dynamic 13C magnetic resonance spectroscopy. Nat Med (2014) 20:98-102. doi:10.1038/nm.3415
11. Jones JG, Solomon MA, Cole SM, Sherry AD, Malloy CR. An integrated (2)H and (13)C NMR study of gluconeogenesis and TCA cycle flux in humans. Am J Physiol Endocrinol Metab (2001) 281:E848-56.
12. Jucker BM, Lee JY, Shulman RG. In vivo 13C NMR measurements of hepatocellular tricarboxylic acid cycle flux. J Biol Chem (1998) 273:12187-94. doi:10.1074/jbc.273.20.12187
13. Shestov AA, Barker B, Gu Z, Locasale JW. Computational approaches for understanding energy metabolism. Wiley Interdiscip Rev Syst Biol Med (2013) 5(6):733-50. doi:10.1002/wsbm.1238
14. Shestov AA, Mancuso A, Lee SC, Guo L, Nelson DS, Roman JC, et al. Bonded cumomer analysis of human melanoma metabolism monitored by 13C NMR spectroscopy of perfused tumor cells. J Biol Chem (2016) 291:5157-71. doi:10.1074/jbc.M115.701862
15. Lee SC, Marzec M, Liu X, Wehrli S, Kantekure K, Ragunath PN, et al. Decreased lactate concentration and glycolytic enzyme expression reflect inhibition of mTOR signal transduction pathway in B-cell lymphoma. NMR Biomed (2013) 26:106-14. doi:10.1002/nbm.2825
16. Lee SC, Delikatny EJ, Poptani H, Pickup S, Glickson JD. In vivo (1)H MRS of WSU-DLCL2 human non-Hodgkin's lymphoma xenografts: response to rituximab and rituximab plus CHOP. NMR Biomed (2009) 22:259-65. doi:10.1002/nbm.1316
17. Lee SC, Huang MQ, Nelson DS, Pickup S, Wehrli S, Adegbola O, et al. In vivo MRS markers of response to CHOP chemotherapy in the WSU-DLCL2 human diffuse large B-cell lymphoma xenograft. NMR Biomed (2008) 21:723-33. doi:10.1002/nbm.1250
18. Maher EA, Marin-Valencia I, Bachoo RM, Mashimo T, Raisanen J, Hatanpaa KJ, et al. Metabolism of U-13C glucose in human brain tumors in vivo. NMR Biomed (2012) 25:1234-44. doi:10.1002/nbm.2794
19. Hensley CT, DeBerardinis RJ. In vivo analysis of lung cancer metabolism: nothing like the real thing. J Clin Invest (2015) 125:495-7. doi:10.1172/JCI79188
20. de Graaf RA, Rothman DL, Behar KL. State of the art direct C-13 and indirect H-1-C-13 NMR spectroscopy in vivo. A practical guide. NMR Biomed (2011) 24:958-72. doi:10.1002/nbm.1761
21. Brindle KM, Bohndiek SE, Gallagher FA, Kettunen MI. Tumor imaging using hyperpolarized C-13 magnetic resonance. Magn Reson Med (2011) 66:505-19. doi:10.1002/mrm.22999
22. Park I, Larson PE, Zierhut ML, Hu S, Bok R, Ozawa T, et al. Hyperpolarized C-13 magnetic resonance metabolic imaging: application to brain tumors. Neuro Oncol (2010) 12:133-44. doi:10.1093/neuonc/nop043
23. Gavva SR, Wiethoff AJ, Zhao PY, Malloy CR, Sherry AD. A C-13 isotopomer NMR method for monitoring incomplete beta-oxidation of fatty-acids in intact tissue. Biochem J (1994) 303:847-53. doi:10.1042/bj3030847
24. Burgess SC, Hausler N, Merritt M, Jeffrey FM, Storey C, Milde A, et al. Impaired tricarboxylic acid cycle activity in mouse livers lacking cytosolic phosphoenolpyruvate carboxykinase. Journal of Biological Chemistry (2004) 279:48941-9. doi:10.1074/jbc.M407120200
25. Burgess SC, He T, Yan Z, Lindner J, Sherry AD, Malloy CR, et al. Cytosolic phosphoenolpyruvate carboxykinase does not solely control the rate of hepatic gluconeogenesis in the intact mouse liver. Cell Metab (2007) 5:313-20. doi:10.1016/j.cmet.2007.03.004
26. Burgess SC, Leone TC, Wende AR, Croce MA, Chen Z, Sherry AD, et al. Diminished hepatic gluconeogenesis via defects in tricarboxylic acid cycle flux in peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha)-deficient mice. J Biol Chem (2006) 281:19000-8. doi:10.1074/jbc.M600050200
27. Hausler N, Browning J, Merritt M, Storey C, Milde A, Jeffrey FM, et al. Effects of insulin and cytosolic redox state on glucose production pathways in the isolated perfused mouse liver measured by integrated H-2 and C-13 NMR. Biochem J (2006) 394:465-73. doi:10.1042/BJ20051174
28. Jin ES, Jones JG, Merritt M, Burgess SC, Malloy CR, Sherry AD. Glucose production, gluconeogenesis, and hepatic tricarboxylic acid cycle fluxes measured by nuclear magnetic resonance analysis of a single glucose derivative. Anal Biochem (2004) 327:149-55. doi:10.1016/j.ab.2003.12.036
29. Jones JG, Naidoo R, Sherry AD, Jeffrey FM, Cottam GL, Malloy CR. Measurement of gluconeogenesis and pyruvate recycling in the rat liver: a simple analysis of glucose and glutamate isotopomers during metabolism of 1, 2, 3-C-13(3) propionate. FEBS Lett (1997) 412:131-7. doi:10.1016/S0014-5793(97)00764-3
30. Sherry AD, Jeffrey FMH, Malloy CR. Analytical solutions for C-13 isotopomer analysis of complex metabolic conditions: substrate oxidation, multiple pyruvate cycles, and gluconeogenesis. Metab Eng (2004) 6:12-24. doi:10.1016/j.ymben.2003.10.007
31. Bachelard H. Landmarks in the application of C-13-magnetic resonance spectroscopy to studies of neuronal/glial relationships. Dev Neurosci (1998) 20:277-88. doi:10.1159/000017322
32. Dusick JR, Glenn TC, Lee WN, Vespa PM, Kelly DF, Lee SM, et al. Increased pentose phosphate pathway flux after clinical traumatic brain injury: a 1, 2-C-13(2) glucose labeling study in humans. J Cereb Blood Flow Metab (2007) 27:1593-602. doi:10.1038/sj.jcbfm.9600458
33. Fan TWM, Lane AN. Structure-based profiling of metabolites and isotopomers by NMR. Prog Nucl Magn Reson Spectrosc (2008) 52:69-117. doi:10.1016/j.pnmrs.2007.03.002
34. Gruetter R, Novotny EJ, Boulware SD, Mason GF, Rothman DL, Shulman GI, et al. Localized C-13 NMR-spectroscopy in the human brain of amino-acid labeling from D-1-C-13 GLUCOSE. J Neurochem (1994) 63:1377-85. doi:10.1046/j.1471-4159.1994.63041377.x
35. Hassel B, Brathe A. Cerebral metabolism of lactate in vivo: evidence for neuronal pyruvate carboxylation. J Cereb Blood Flow Metab (2000) 20:327-36. doi:10.1097/00004647-200002000-00014
36. Henry PG, Tkac I, Gruetter R. H-1-localized broadband C-13 NMR spectroscopy of the rat brain in vivo at 9.4 T. Magn Reson Med (2003) 50:684-92. doi:10.1002/mrm.10601
37. Kunnecke B, Cerdan S, Seelig J. Cerebral metabolism of 1, 2-C-13(2) glucose and U-C-13(4) 3-hydroxybutyrate in rat-brain as detected by C-13 NMR-spectroscopy. NMR Biomed (1993) 6:264-77. doi:10.1002/nbm.1940060406
38. Lapidot A, Gopher A. Cerebral metabolic compartmentation-estimation of glucose flux via pyruvate-carboxylase pyruvate-dehydrogenase by C-13 NMR isotopomer analysis of D-U-C-13 glucose metabolites. J Biol Chem (1994) 269:27198-208.
39. Mason GF, Rothman DL. Basic principles of metabolic modeling of NMR C-13 isotopic turnover to determine rates of brain metabolism in vivo. Metab Eng (2004) 6:75-84. doi:10.1016/j.ymben.2003.10.003
40. Oz G, Berkich DA, Henry PG, Xu Y, LaNoue K, Hutson SM, et al. Neuroglial metabolism in the awake rat brain: CO2 fixation increases with brain activity. Journal of Neuroscience (2004) 24:11273-9. doi:10.1523/JNEUROSCI.3564-04.2004
41. Zwingmann C, Richter-Landsberg C, Brand A, Leibfritz D. NMR spectroscopic study on the metabolic fate of 3-C-13 alanine in astrocytes, neurons, and cocultures: implications for glia-neuron interactions in neurotransmitter metabolism. Glia (2000) 32:286-303. doi:10.1002/1098-1136(200012)32:3<286::AID-GLIA80>3.0.CO;2-P
42. Zwingmann C, Richter-Landsberg C, Leibfritz D. C-13 isotopomer analysis of glucose and alanine metabolism reveals cytosolic pyruvate compartmentation as part of energy metabolism in astrocytes. Glia (2001) 34:200-12. doi:10.1002/glia.1054
43. Wiechert W, Mollney M, Isermann N, Wurzel M, de Graaf AA. Bidirectional reaction steps in metabolic networks: III. Explicit solution and analysis of isotopomer labeling systems. Biotechnol Bioeng (1999) 66:69-85. doi:10.1002/(SICI)1097-0290(1999)66:2<69::AID-BIT1>3.0.CO;2-6
44. Antoniewicz MR, Kelleher JK, Stephanopoulos G. Elementary metabolite units (EMU): a novel framework for modeling isotopic distributions. Metab Eng (2007) 9:68-86. doi:10.1016/j.ymben.2006.09.001
45. Shestov AA, Valette J, Deelchand DK, Ugurbil K, Henry PG. Metabolic modeling of dynamic brain C-13 NMR multiplet data: concepts and simulations with a two-compartment neuronal-glial model. Neurochem Res (2012) 37:2388-401. doi:10.1007/s11064-012-0782-5
46. Shestov AA, Mancuso A, Leeper DB, Glickson JD. Metabolic network analysis of DB1 melanoma cells: how much energy is derived from aerobic glycolysis? Adv Exp Med Biol (2013) 765:265-71. doi:10.1007/978-1-4614-4989-8_37
47. Guo L, Shestov AA, Worth AJ, Nath K, Nelson DS, Leeper DB, et al. Inhibition of mitochondrial complex II by the anticancer agent lonidamine. J Biol Chem (2016) 291:42-57. doi:10.1074/jbc.M115.697516
48. Mehrmohamadi M, Liu XJ, Shestov AA, Locasale JW. Characterization of the usage of the serine metabolic network in human cancer. Cell Rep (2014) 9:1507-19. doi:10.1016/j.celrep.2014.10.026
49. Tzika AA, Fontes-Oliveira CC, Shestov AA, Constantinou C, Psychogios N, Righi V, et al. Skeletal muscle mitochondrial uncoupling in a murine cancer cachexia model. Int J Oncol (2013) 43:886-94. doi:10.3892/ijo.2013.1998
50. Wahl ML, Owen JA, Burd R, Herlands RA, Nogami SS, Rodeck U, et al. Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol Cancer Ther (2002) 1:617-28.
51. Fox JEM, Meredith D, Halestrap AP. Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle. J Physiol (2000) 529:285-93. doi:10.1111/j.1469-7793.2000.00285.x
52. Nancolas B, Sessions RB, Halestrap AP. Identification of key binding site residues of MCT1 for AR-C155858 reveals the molecular basis of its isoform selectivity. Biochem J (2015) 466:177-88. doi:10.1042/BJ20141223
53. Ovens MJ, Davies AJ, Wilson MC, Murray CM, Halestrap AP. AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10. Biochem J (2010) 425:523-30. doi:10.1042/BJ20091515
54. Bricker DK, Taylor EB, Schell JC, Orsak T, Boutron A, Chen YC, et al. A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans. Science (2012) 337:96-100. doi:10.1126/science.1218099
55. Halestrap AP. The mitochondrial pyruvate carrier: has it been unearthed at last? Cell Metab (2012) 16:141-3. doi:10.1016/j.cmet.2012.07.013
56. Herzig S, Raemy E, Montessuit S, Veuthey JL, Zamboni N, Westermann B, et al. Identification and functional expression of the mitochondrial pyruvate carrier. Science (2012) 337:93-6. doi:10.1126/science.1218530
57. Muzykantov VS, Shestov AA. Kinetic equations for the redistribution of isotopic molecules due to reversible dissociation. Homoexchange of methane. React Kinetics Catal Lett (1986) 32(2):307-12.
58. Shestov AA, Valette J, Ugurbil K, Henry PG. On the reliability of (13)C metabolic modeling with two-compartment neuronal-glial models. J Neurosci Res (2007) 85:3294-303. doi:10.1002/jnr.21269
59. Heinrich R, Rapoport TA. A linear steady-state treatment of enzymatic chains. General properties, control and effector strength. Eur J Biochem (1974) 42:89-95. doi:10.1111/j.1432-1033.1974.tb03319.x
60. Kacser H, Burns JA. The control of flux. Symp Soc Exp Biol (1973) 27: 65-104.
61. Hill LL, Korngold R, Jaworsky C, Murphy G, McCue P, Berd D. Growth and metastasis of fresh human melanoma tissue in mice with severe combined immunodeficiency. Cancer Res (1991) 51:4937-41.
62. Mancuso A, Beardsley NJ, Wehrli S, Pickup S, Matschinsky FM, Glickson JD. Real-time detection of 13C NMR labeling kinetics in perfused EMT6 mouse mammary tumor cells and betaHC9 mouse insulinomas. Biotechnol Bioeng (2004) 87:835-48. doi:10.1002/bit.20191
63. Bental M, Pick U, Avron M, Degani H. Metabolic studies with NMR-spectroscopy of the alga dunaliella-salina trapped within agarose beads. Eur J Biochem (1990) 188:111-6. doi:10.1111/j.1432-1033.1990.tb15377.x
64. Mancuso A, Fernandez EJ, Blanch HW, Clark DS. A nuclear magnetic resonance technique for determining hybridoma cell concentration in hollow fiber bioreactors. Biotechnology (N Y) (1990) 8:1282-5. doi:10.1038/nbt1290-1282
65. Leeper DB, Engin K, Thistlethwaite AJ, Hitchon HD, Dover JD, Li DJ, et al. Human tumor extracellular pH as a function of blood glucose concentration. Int J Radiat Oncol Biol Phys (1994) 28:935-43. doi:10.1016/0360-3016(94)90114-7
66. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res (1989) 49:4373-84.
67. Mancuso A, Zhu A, Beardsley NJ, Glickson JD, Wehrli S, Pickup S. Artificial tumor model suitable for monitoring 31P and 13C NMR spectroscopic changes during chemotherapy-induced apoptosis in human glioma cells. Magn Reson Med (2005) 54:67-78. doi:10.1002/mrm.20545
68. Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, et al. The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 10:85. doi:10.1186/1479-5876-10-85
69. Kaplon J, Zheng L, Meissl K, Chaneton B, Selivanov VA, Mackay G, et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature (2013) 498:109-12. doi:10.1038/nature12154
70. Mullen AR, Hu Z, Shi X, Jiang L, Boroughs LK, Kovacs Z, et al. Oxidation of alpha-ketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects. Cell Rep (2014) 7:1679-90. doi:10.1016/j.celrep.2014.04.037
71. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A (2007) 104:19345-50. doi:10.1073/pnas.0709747104
72. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A (2008) 105:18782-7. doi:10.1073/pnas.0810199105
73. Rajagopalan KN, DeBerardinis RJ. Role of glutamine in cancer: therapeutic and imaging implications. J Nucl Med (2011) 52:1005-8. doi:10.2967/jnumed.110.084244
74. Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest (2013) 123:3678-84. doi:10.1172/JCI69600
75. Le A, Dang CV. Studying Myc's role in metabolism regulation. Methods Mol Biol (2013) 1012:213-9. doi:10.1007/978-1-62703-429-6_14
76. Fan J, Kamphorst JJ, Mathew R, Chung MK, White E, Shlomi T, et al. Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia. Mol Syst Biol (2013) 9:712. doi:10.1038/msb.2013.65
77. Scott DA, Richardson AD, Filipp FV, Knutzen CA, Chiang GG, Ronai ZA, et al. Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect. J Biol Chem (2011) 286:42626-34. doi:10.1074/jbc.M111.282046
78. Schug ZT, Peck B, Jones DT, Zhang Q, Grosskurth S, Alam IS, et al. Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell (2015) 27:57-71. doi:10.1016/j.ccell.2014.12.002
79. Fan J, Ye J, Kamphorst JJ, Shlomi T, Thompson CB, Rabinowitz JD. Quantitative flux analysis reveals folate-dependent NADPH production. Nature (2014) 510:298-302. doi:10.1038/nature13236
80. Marzec M, Kasprzycka M, Liu X, El-Salem M, Halasa K, Raghunath PN, et al. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene (2007) 26:5606-14. doi:10.1038/sj.onc.1209843
81. Marzec M, Liu X, Kasprzycka M, Witkiewicz A, Raghunath PN, El-Salem M, et al. IL-2-and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4(+) T lymphocytes. Blood (2008) 111:2181-9. doi:10.1182/blood-2007-06-095182
82. Wlodarski P, Kasprzycka M, Liu X, Marzec M, Robertson ES, Slupianek A, et al. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-1, and serum. Cancer Res (2005) 65:7800-8. doi:10.1158/0008-5472.CAN-04-4180
83. Corradetti MN, Guan KL. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene (2006) 25:6347-60. doi:10.1038/sj.onc.1209885
84. Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer (2006) 94:195-9. doi:10.1038/sj.bjc.6602902
85. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer (2006) 6:729-34. doi:10.1038/nrc1974
86. Arvisais EW, Romanelli A, Hou XY, Davis JS. AKT-independent phosphorylation of TSC2 and activation of mTOR and ribosomal protein S6 kinase signaling by prostaglandin F2 alpha. J Biol Chem (2006) 281:26904-13. doi:10.1074/jbc.M605371200
87. Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ. Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood (2007) 110:278-86. doi:10.1182/blood-2006-08-039883
88. Sakata A, Kuwahara K, Ohmura T, Inui S, Sakaguchi N. Involvement of a rapamycin-sensitive pathway in CD40-mediated activation of murine B cells in vitro. Immunol Lett (1999) 68:301-9. doi:10.1016/S0165-2478(99)00053-X
89. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A (2006) 103:5466-71. doi:10.1073/pnas.0509694103
90. Suh JM, Song JH, Kim DW, Kim H, Chung HK, Hwang JH, et al. Regulation of the phosphatidylinositol 3-kinase, Akt/protein kinase B, FRAP/mammalian target of rapamycin, and ribosomal S6 kinase 1 signaling pathways by thyroid-stimulating hormone (TSH) and stimulating type TSH receptor antibodies in the thyroid gland. Journal of Biological Chemistry (2003) 278:21960-71. doi:10.1074/jbc.M300805200
91. Wing LYC, Chen HM, Chuang PC, Wu MH, Tsai SJ. The mammalian target of rapamycin-p70 ribosomal S6 kinase but not phosphatidylinositol 3-kinase-Akt signaling is responsible for fibroblast growth factor-9-induced cell proliferation. J Biol Chem (2005) 280:19937-47. doi:10.1074/jbc.M411865200
92. Nave BT, Ouwens DM, Withers DJ, Alessi DR, Shepherd PR. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J (1999) 344:427-31. doi:10.1042/0264-6021:3440427
93. Sekulic A, Hudson CC, Homme JL, Yin P, Otterness DM, Karnitz LM, et al. A direct linkage between the phosphoinositide 3-Kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res (2000) 60:3504-13.
94. Tee AR, Anjum R, Blenis J. Inactivation of the tuberous sclerosis complex-1 and-2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and-independent phosphorylation of tuberin. J Biol Chem (2003) 278:37288-96. doi:10.1074/jbc.M303257200
95. Ma L, Chen ZB, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk: implications for tuberous sclerosis and cancer pathogenesis. Cell (2005) 121:179-93. doi:10.1016/j.cell.2005.02.031
96. Leseux L, Hamdi SM, Al Saati T, Capilla F, Recher C, Laurent G, et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood (2006) 108:4156-62. doi:10.1182/blood-2006-05-026203
97. Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res (2004) 10:6661-8. doi:10.1158/1078-0432.CCR-04-0039
98. Kominsky DJ, Klawitter J, Brown JL, Boros LG, Melo JV, Eckhardt SG, et al. Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. Clinical Cancer Research (2009) 15:3442-50. doi:10.1158/1078-0432.CCR-08-3291
99. Carayol N, Katsoulidis E, Sassano A, Altman JK, Druker BJ, Platanias LC. Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway. Journal of Biological Chemistry (2008) 283:8601-10. doi:10.1074/jbc.M707934200
100. Düvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell (2010) 39:171-83. doi:10.1016/j.molcel.2010.06.022
101. Nath K, Nelson DS, Ho AM, Lee SC, Darpolor MM, Pickup S, et al. 31P and 1H MRS of DB-1 melanoma xenografts: lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan. NMR Biomed (2013) 26(1):98-105. doi:10.1002/nbm.2824
102. DeBrosse C, Nanga RP, Bagga P, Nath K, Haris M, Marincola F, et al. Lactate chemical exchange saturation transfer (LATEST) imaging in vivo: a biomarker for LDH activity. Sci Rep (2016) 6:19517. doi:10.1038/srep19517